Professor Gordon Jayson  FRCP PhD

2012

• Marti-Marti FE, Miles L, Connell J, Allen J, Jayson G, Renehan A, Dive C. (2012). A NOVEL TRIAL DESIGN FOR RECTAL CANCER: THE DREAMtherapy TRIAL (Dual REctal Angiogenesis MEK inhibition radioTherapy). Presented at 14th World Congress on Gastrointestinal Cancer. Barcelona Spain. eScholarID:155243
• Marti-Marti FE, Miles, L, Allen J, Connell J, Rowland S, Backen A, Renehan A, Manoharan P, Misra V, Jackson A, Ataman O, Jayson GC, Dive C, Saunders MP. (2012). First results from the phase I dual rectal angiogenesis MEK inhibition radiotherapy (DREAMtherapy) trial in locally advanced rectal cancer. Presented at ASCO Annual Meeting. Chicago USA. eScholarID:155167
• Horsley, L., Marti, K. & Jayson, G (2012). Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy. Expert Opin Drug Metab Toxicol, eScholarID:155166 | PMID:22283844 | DOI:10.1517/17425255.2012.656845

2011

• Buonaccorsi GA, Roberts C, O'Connor JP, Rose CJ, Cheung S, Watson Y, Jackson A, Jayson GC, Parker GJ. (2011). Tracer-kinetic model-driven registration improves data-driven tumour sub-segmentation of DCE-MRI data. Presented at International Society for Magnetic Resonance in Medicine, 19th Scientific Meeting and Exhibition. Montreal, Canada. eScholarID:123700
• Hansen SU, Miller GJ, Barath M, Broberg K, Avizienyte E, Cole C, Rushton G, Jayson GC, Gardiner JM. (2011). Synthesis and Evaluation of Heparin Sulfate Oligosaccharides. Presented at 16th European Carbohydrate Symposium. Sorrento. eScholarID:121897
• Hansen SU, Miller GJ, Barath M, Broberg K, Avizienyte E, Cole C, Rushton G, Jayson GC, Gardiner JM. (2011). Synthesis and Evaluation of Heparin Sulfate Oligosaccharides. Presented at 17th European Symposium on Organic Chemistry. Crete. eScholarID:121898
• Marti F, Miles L, Connell J, Allen J, Renehan A, Jackson A, Parker G, Jayson G, Dive C, Saunders M. (2011). A novel trial design for rectal cancer: the DREAMtherapy Trial (Dual REctal Angiogenesis MEK inhibition radiotherapy). Presented at ESMO 13th World Congress on Gastrointestinal Cancer. Barcelona, Spain. eScholarID:124420
• Banerji A, Naish JH, Watson Y, Jayson GC, Buonaccorsi GA, Parker GJ. (2011). 98. DCE-MRI model selection for investigating disruption of microvascular function in livers with metastatic disease. Journal of Magnetic Resonance Imaging, 35(1), 196-203. eScholarID:142065
• Danielle L. Shaw and Gordon C. Jayson. (2011). Angiogenesis: A Target for the Treatment of Ovarian Cancer. Treatment Strategies - Oncology, 2(2), 72-78. eScholarID:142171
• Gonçalves, V., Jayson, G. & Tarrier, N (2011). A longitudinal investigation of posttraumatic stress disorder in patients with ovarian cancer. J Psychosom Res, 70(5), 422-31. eScholarID:122326 | PMID:21511072 | DOI:10.1016/j.jpsychores.2010.09.017
• Griffiths, R., Zee, Y., Evans, S., Mitchell, C., Kumaran, G., Welch, R., Jayson, G., Clamp, A. & Hasan, J (2011). Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube. Int J Gynecol Cancer, 21(1), 58-65. eScholarID:103961 | PMID:21178570 | DOI:10.1097/IGC.0b013e3182049273
• Hackshaw A, Kaye SB, Jayson GC, Gabra H, McNeish I, Persic M, Adams M, James L, Temple G, Merger M, Rustin G. (2011). A randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 following chemotherapy for relapsed ovarian cancer. Journal of Clinical Oncology, 29(28), 3798-3804. eScholarID:142445 | DOI:10.1200/JCO.2010.33.5208
• Jayson, G (2011). VEGF inhibitors and advanced ovarian cancer. Lancet Oncol, 12(12), 1082-3. eScholarID:145274 | PMID:21992854 | DOI:10.1016/S1470-2045(11)70269-8
• Jonker DJ, Rosen LS, Sawyer MB, de Braud F, Wilding G, Sweeney CJ, Jayson GC, McArthur GA, Rustin G, Goss G, Kantor J, Velasquez L, Syed S, Mokliatchouk O, Feltquate DM, Kollia G, Nuyten DS, Galbraith S. (2011). A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Annals of Oncology, 22(6), 1413-1419. eScholarID:142167 | DOI:10.1093/annonc/mdq599
• Ledermann, J., Hackshaw, A., Kaye, S., Jayson, G., Gabra, H., McNeish, I., Earl, H., Perren, T., Gore, M., Persic, M., Adams, M., James, L., Temple, G., Merger, M. & Rustin, G (2011). Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol, 29(28), 3798-804. eScholarID:155056 | PMID:21859991 | DOI:10.1200/JCO.2010.33.5208
• O'Connor JP, Rose CJ, Jackson A, Watson Y, Cheung S, Maders F, Whitcher BJ, Roberts C, Buonaccorsi GA, Thompson G, Clamp AR, Jayson GC, Parker GJ. (2011). DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. British Journal of Cancer, 105(1), 139-145. eScholarID:153174 | DOI:10.1038/bjc.2011.191
• O'Connor, J., Rose, C., Jackson, A., Watson, Y., Cheung, S., Maders, F., Whitcher, B., Roberts, C., Buonaccorsi, G., Thompson, G., Clamp, A., Jayson, G. & Parker, G (2011). DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br J Cancer, eScholarID:124419 | PMID:21673686 | DOI:10.1038/bjc.2011.191
• Perren, T., Swart, A., Pfisterer, J., Ledermann, J., Pujade-Lauraine, E., Kristensen, G., Carey, M., Beale, P., Cervantes, A., Kurzeder, C., du Bois, A., Sehouli, J., Kimmig, R., Stähle, A., Collinson, F., Essapen, S., Gourley, C., Lortholary, A., Selle, F., Mirza, M., Leminen, A., Plante, M., Stark, D., Qian, W., Parmar, M., Oza, A. & . (2011). A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med, 365(26), 2484-96. eScholarID:145273 | PMID:22204725 | DOI:10.1056/NEJMoa1103799
• Rustin, G., Reed, N., Jayson, G., Ledermann, J., Adams, M., Perren, T., Poole, C., Lind, M., Persic, M., Essapen, S., Gore, M., Calvert, H., Stredder, C., Wagner, A., Giurescu, M. & Kaye, S (2011). A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Ann Oncol, eScholarID:120175 | PMID:21372124 | DOI:10.1093/annonc/mdq780
• Zweifel M, Jayson GC, Reed NS, Osborne R, Hassan B, Ledermann J, Shreeves G, Poupard L, Lu SP, Balkissoon J, Chaplin DJ, Rustin GJ. (2011). Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol, eScholarID:117081
• Zweifel M, Jayson GC, Reed NS, Osborne R, Hassan B, Ledermann J, Shreeves G, Poupard L, Lu SP, Balkissoon J, Chaplin DJ, Rustin GJ. (2011). Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Annals of Oncology, 22(9), 2036-2041. eScholarID:142166 | DOI:10.1093/annonc/mdq708

2010

• 148 Ledermann JA, Gabra H, Jayson GC, Spanswick VJ, Rustin GJ, Jitlal M, James L, Hartley JA. (2010). Inhibition of carboplatin-induced DNA interstrand crosslink repair by gemcitabine in patients receiving these drugs for 'platinum-resistant' ovarian cancer. Clinical Cancer Research, eScholarID:88455
• 85 Buonaccorsi GA, Rose CJ, O'Connor JP, Roberts C, Watson Y, Jackson A, Jayson GC, Parker GJ. (2010). Cross-visit tumor sub-segmentation and registration with outlier rejection for dynamic contrast-enhanced MRI time series data. Med Image Comput Comput Assist Interv, 13, 121-128. eScholarID:92522
• 86 Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM. (2010). Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet, 1155-1163. eScholarID:92521 | DOI:10.1016/S0140-6736(10)61268-8
• Cole CL, Hansen SU, Baráth M, Rushton G, Gardiner JM, Avizienyte E, Jayson GC. (2010). Synthetic heparan sulfate oligosaccharides inhibit endothelial cell functions essential for angiogenesis. PLoS ONE, 5(7), eScholarID:142437 | DOI:10.1371/journal.pone.0011644
• Cole, C., Lau, S., Backen, A., Clamp, A., Rushton, G., Dive, C., Hodgkinson, C., McVey, R., Kitchener, H. & Jayson, G (2010). Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther, 10(5), 495-504. eScholarID:123699 | PMID:20595807 | DOI:10.4161/cbt.10.5.12585
• Goncalves VMO, Jayson GC. (2010). Longitudinal investigation of post-traumatic stress disorder in patients with ovarian cancer. Journal of Psychosomatic Research (in press Nov2010), eScholarID:94274
• Jonker, D., Rosen, L., Sawyer, M., de Braud, F., Wilding, G., Sweeney, C., Jayson, G., McArthur, G., Rustin, G., Goss, G., Kantor, J., Velasquez, L., Syed, S., Mokliatchouk, O., Feltquate, D., Kollia, G., Nuyten, D. & Galbraith, S (2010). A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Ann Oncol, eScholarID:98944 | PMID:21131369 | DOI:10.1093/annonc/mdq599
• Ledermann, J., Gabra, H., Jayson, G., Spanswick, V., Rustin, G., Jitlal, M., James, L. & Hartley, J (2010). Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer. Clin Cancer Res, 16(19), 4899-905. eScholarID:120176 | PMID:20719935 | DOI:10.1158/1078-0432.CCR-10-0832
• Mitchell CL, O'Connor JP, Jackson A, Parker GJ, Roberts C, Watson Y, Cheung S, Davies K, Buonaccorsi GA, Clamp AR, Hasan J, Byrd L, Backen A, Dive C, Jayson GC. (2010). Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy. Ann Oncol, (10), 1982-1989. eScholarID:117084
• Mitchell CL, O'Connor JP, Roberts C, Watson Y, Jackson A, Cheung S, Evans J, Spicer J, Harris A, Kelly C, Rudman S, Middleton M, Fielding A, Tessier J, Young H, Parker GJ, Jayson GC. (2010). A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. Cancer Chemother Pharmacol, eScholarID:96959
• Mitchell, C., O'Connor, J., Roberts, C., Watson, Y., Jackson, A., Cheung, S., Evans, J., Spicer, J., Harris, A., Kelly, C., Rudman, S., Middleton, M., Fielding, A., Tessier, J., Young, H., Parker, G. & Jayson, G (2010). A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. Cancer Chemother Pharmacol, eScholarID:98943 | PMID:21120480 | DOI:10.1007/s00280-010-1534-3
• Zee YK, Chan SW, Harris J, Jayson GC. (2010). The ethical and scientific case for phase 2C clinical trials. Lancet Oncology, 11(5), 410-411. eScholarID:142439 | DOI:10.1016/S1470-2045(10)70093-0
• Kumaran, Gireesh. (2010). Pre-clinical and early clinical evaluation of GSAO. The University of Manchester. eScholarID:123698
• Mitchell, Claire. (2010). The development of new imaging strategies of human tumour vasculature. The University of Manchester. eScholarID:123697

2009

• 77. O’Connor J, Carano RAD, Clamp AR, Ross J, Ho CK, Jackson A, Parker GJM, Rose CJ, Peale FV, Friesenhahn M, Mitchell CM, Watson Y, Roberts C, Hope L, Cheung S, Reslan HB, Go MA, Pacheco G, Wu X, Cao T, Ross S, Buonaccorsi GA, Davies G, Hasan J, Thornton P, del Puerto O, Ferrara N, van Bruggen N, Jayson GC. 15(21). (2009). Rapid anti-vascular effects induced by selective VEGF blockade lead to tumor shrinkage in CRC within a single cycle of therapy. Clinical Cancer Research, 15(21), 6674-6682. eScholarID:142435
• Backen A, Cummings J, Mitchell CL, Jayson G-, Ward T, Dive C. (2009). 'Fit-for-purpose' validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use. J Immunol Methods, 342( 1-2), eScholarID:1d19956 | DOI:10.1016/j.jim.2009.01.003
• Collinson, F. & Jayson, G (2009). New therapeutic agents in ovarian cancer. Curr Opin Obstet Gynecol, 21(1), 44-53. eScholarID:82727 | DOI:10.1097/GCO.0b013e32831ffe71
• Hansen, S., Barath, M., Salameh, B., Pritchard, R., Stimpson, W., Gardiner, J. & Jayson, G (2009). Scalable synthesis of L-iduronic acid derivatives via stereocontrolled cyanohydrin reaction for synthesis of heparin-related disaccharides. Org Lett, 11(20), 4528-31. eScholarID:82740 | DOI:10.1021/ol901723m
• Kumaran GC, Jayson GC, Clamp AR. (2009). Antiangiogenic drugs in ovarian cancer. Br J Cancer, 100(1), 1-7. eScholarID:1d32387 | DOI:10.1038/sj.bjc.6604767
• O'Connor, J., Carano, R., Clamp, A., Ross, J., Ho, C., Jackson, A., Parker, G., Rose, C., Peale, F., Friesenhahn, M., Mitchell, C., Watson, Y., Roberts, C., Hope, L., Cheung, S., Reslan, H., Go, M., Pacheco, G., Wu, X., Cao, T., Ross, S., Buonaccorsi, G., Davies, K., Hasan, J., Thornton, P., del, P., Ferrara, N., van, B. & Jayson, G (2009). Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res, 15(21), 6674-82. eScholarID:82739 | DOI:10.1158/1078-0432.CCR-09-0731
• O'Connor, J., Naish, J., Jackson, A., Waterton, J., Watson, Y., Cheung, S., Buckley, D., McGrath, D., Buonaccorsi, G., Mills, S., Roberts, C., Jayson, G. & Parker, G (2009). Comparison of normal tissue R1 and R*2 modulation by oxygen and carbogen. Magn Reson Med, 61(1), 75-83. eScholarID:82744 | DOI:10.1002/mrm.21815
• O'Connor, J., Naish, J., Parker, G., Waterton, J., Watson, Y., Jayson, G., Buonaccorsi, G., Cheung, S., Buckley, D., McGrath, D., West, C., Davidson, S., Roberts, C., Mills, S., Mitchell, C., Hope, L., Ton, N. & Jackson, A (2009). Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel biomarker of oxygenation changes in solid tumors. Int J Radiat Oncol Biol Phys, 75(4), 1209-15. eScholarID:82741 | DOI:10.1016/j.ijrobp.2008.12.040

2008

• Byrd, L., Shenton, A., Maher, E., Woodward, E., Belk, R., Lim, C., Lalloo, F., Howell, A., Jayson, G. & Evans, G (2008). Better life expectancy in women with BRCA2 compared with BRCA1 mutations is attributable to lower frequency and later onset of ovarian cancer. Cancer Epidemiol Biomarkers Prev, 17(6), 1535-42. eScholarID:82734 | DOI:10.1158/1055-9965.EPI-07-2792
• Clamp, A., Schoffski, P., Valle, J., Wilson, R., Marreaud, S., Govaerts, A., Debois, M., Lacombe, D., Twelves, C., Chick, J. & Jayson, G (2008). A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemother Pharmacol, 61(4), 579-85. eScholarID:82737 | DOI:10.1007/s00280-007-0509-5
• Cole, C. & Jayson, G (2008). Oligosaccharides as anti-angiogenic agents. Expert Opin Biol Ther, 8(3), 351-62. eScholarID:82735 | DOI:10.1517/14712598.8.3.351
• Collinson, F., Hall, G., Perren, T. & Jayson, G (2008). Development of antiangiogenic agents for ovarian cancer. Expert Rev Anticancer Ther, 8(1), 21-32. eScholarID:82736 | DOI:10.1586/14737140.8.1.21
• Goncalves, V., Jayson, G. & Tarrier, N (2008). A longitudinal investigation of psychological morbidity in patients with ovarian cancer. Br J Cancer, 99(11), 1794-801. eScholarID:82728 | DOI:10.1038/sj.bjc.6604770
• Kumaran, G., Clamp, A. & Jayson, G (2008). Angiogenesis as a therapeutic target in cancer. Clin Med, 8(4), 455-8. eScholarID:82731
• O'Connor, J., Jackson, A., Asselin, M., Buckley, D., Parker, G. & Jayson, G (2008). Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. Lancet Oncol, 9(8), 766-76. eScholarID:82732 | DOI:10.1016/S1470-2045(08)70196-7
• Sweeney E, Ward T, Gray N, Womack C, Jayson G-, Hughes A, Dive C, Byers RJ. (2008). Quantitative multiplexed quantum dot immunohistochemistry. Biochem Biophys Res Commun, 374( 2), eScholarID:1d19949 | DOI:10.1016/j.bbrc.2008.06.127
• Sweeney, E., Ward, T., Gray, N., Womack, C., Jayson, G., Hughes, A., Dive, C. & Byers, R (2008). Quantitative multiplexed quantum dot immunohistochemistry. Biochem Biophys Res Commun, 374(2), 181-6. eScholarID:82733 | DOI:10.1016/j.bbrc.2008.06.127

2007

• Backen, A., Cole, C., Lau, S., Clamp, A., McVey, R., Gallagher, J. & Jayson, G (2007). Heparan sulphate synthetic and editing enzymes in ovarian cancer. Br J Cancer, 96(10), 1544-8. eScholarID:82770
• Buonaccorsi, G, O'Connor, JP B, Caunce, A, Roberts, C, Cheung, SW, Watson, Y, Davies, KE, Jackson, A-, Jayson, G-, Parker, GJM. (2007). Tracer kinetic model driven registration for DCE-MRI time-series data. Magnetic Resonance In Medicine, 58, eScholarID:1d27903
• Buonaccorsi, G., O'Connor, J., Caunce, A., Roberts, C., Cheung, S., Watson, Y., Davies, K., Hope, L., Jackson, A., Jayson, G. & Parker, G (2007). Tracer kinetic model-driven registration for dynamic contrast-enhanced MRI time-series data. Magn Reson Med, 58(5), 1010-9. eScholarID:82755
• Byrd, L., Thistlethwaite, F., Clamp, A., Ton, C., Hasan, J. & Jayson, G (2007). Weekly paclitaxel in the treatment of recurrent ovarian carcinoma. Eur J Gynaecol Oncol, 28(3), 174-8. eScholarID:82765
• Duff, S., Jeziorska, M., Kumar, S., Haboubi, N., Sherlock, D., O'Dwyer, S. & Jayson, G (2007). Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer. Colorectal Dis, 9(9), 793-800. eScholarID:82759
• Jackson, A., O'Connor, J., Parker, G. & Jayson, G (2007). Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res, 13(12), 3449-59. eScholarID:82767
• Mullamitha, S., Ton, N., Parker, G., Jackson, A., Julyan, P., Roberts, C., Buonaccorsi, G., Watson, Y., Davies, K., Cheung, S., Hope, L., Valle, J., Radford, J., Lawrance, J., Saunders, M., Munteanu, M., Nakada, M., Nemeth, J., Davis, H., Jiao, Q., Prabhakar, U., Lang, Z., Corringham, R., Beckman, R. & Jayson, G (2007). Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res, 13(7), 2128-35. eScholarID:82772
• Nemeth, J., Nakada, M., Trikha, M., Lang, Z., Gordon, M., Jayson, G., Corringham, R., Prabhakar, U., Davis, H. & Beckman, R (2007). Alpha-v integrins as therapeutic targets in oncology. Cancer Invest, 25(7), 632-46. eScholarID:82752
• O'Connor JP B, Jackson A-, Parker GJM, Jayson G-. (2007). DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. British Journal Of Cancer, 96, eScholarID:1d27616
• O'Connor, JP B, Jackson, A-, Giovanni Buonccoris, Watson, Y, Cheung, SW, Roberts, C, McGrath, DM, Rose, CJ, Dark, PM, Jayson, G-, Buckley, DL, Parker, GJM. (2007). Organ-specific effects of oxygen and carbogen gas inhalation on tissue longitudinal relaxation times. Magnetic Resonance in Medicine, 58(3), 490-496. eScholarID:1d14022
• O'Connor, JP B, Jayson, G-, Jackson, A-, Ghiorghiu, Dana, Carrington, B, Rose, CJ, Mills, S, Swindell, R, Roberts, C, Mitchell, CL, Parker, GJM. (2007). Enhancing fraction predicts clinical outcome following first line chemotherapy in patients with epithelial ovarian carcinoma. Clinical Cancer Research, 13(20), 6130-6135. eScholarID:1d27901
• Ralph, S., Brenchley, P., Summers, A., Rosa, D., Swindell, R. & Jayson, G (2007). Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma. Cancer Sci, 98(6), 844-9. eScholarID:82771
• Rosa DD, Ton NC, Clamp A, Mullamitha S, Lau S, Clayton R, Kitchener HC, Shanks JH, McVey R, Jayson GC. (2007). The Neoadjuvant Approach in the Treatment of Patients with Advanced Epithelial Ovarian Carcinoma. Clinical Oncology, 125-128. eScholarID:89823
• Rosa, D., Clamp, A., Collinson, F. & Jayson, G (2007). Antiangiogenic therapy for ovarian cancer. Curr Opin Oncol, 19(5), 497-505. eScholarID:82763
• Rose, C., Mills, S., O'Connor, J., Buonaccorsi, G., Roberts, C., Watson, Y., Whitcher, B., Jayson, G., Jackson, A. & Parker, G (2007). Quantifying heterogeneity in dynamic contrast-enhanced MRI parameter maps. Med Image Comput Comput Assist Interv, 10(Pt 2), 376-84. eScholarID:82750
• Ton, N., Parker, G., Jackson, A., Mullamitha, S., Buonaccorsi, G., Roberts, C., Watson, Y., Davies, K., Cheung, S., Hope, L., Power, F., Lawrance, J., Valle, J., Saunders, M., Felix, R., Soranson, J., Rolfe, L., Zinkewich-Peotti, K. & Jayson, G (2007). Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin Cancer Res, 13(23), 7113-8. eScholarID:82748

2006

• Baka, S., Clamp, A. & Jayson, G (2006). A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin Ther Targets, 10(6), 867-76. eScholarID:82787
• Board, R., Bruijns, C., Pronk, A., Ryder, W., Wilkinson, P., Welch, R., Shanks, J., Connolly, G., Slade, R., Reynolds, K., Kitchener, H. & Jayson, G (2006). Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center. Int J Gynecol Cancer, 16 Suppl 1, 18-24. eScholarID:82781
• Buonaccorsi GA, Roberts C, Cheung S, Watson Y, O'connor JP, Davies K, Jackson A, Jayson GC, Parker GJ. (2006). Comparison of the performance of tracer kinetic model-driven registration for dynamic contrast enhanced MRI using different models of contrast enhancement. Magn Reson Med, 993-1000. eScholarID:89822
• Buonaccorsi, G., Roberts, C., Cheung, S., Watson, Y., O'Connor, J., Davies, K., Jackson, A., Jayson, G. & Parker, G (2006). Comparison of the performance of tracer kinetic model-driven registration for dynamic contrast enhanced MRI using different models of contrast enhancement. Acad Radiol, 13(9), 1112-23. eScholarID:82789
• Clamp AR, Mäenpää J, Cruickshank D, Ledermann J, Wilkinson PM, Welch R, Chan S, Vasey P, Sorbe B, Hindley A and Jayson GC. (2006). SCOTROC 2B: Feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer. 55-61. eScholarID:89818
• Clamp, A., Blackhall, F., Henrioud, A., Jayson, G., Javaherian, K., Esko, J., Gallagher, J. & Merry, C (2006). The morphogenic properties of oligomeric endostatin are dependent on cell surface heparan sulfate. J Biol Chem, 281(21), 14813-22. eScholarID:82782
• Clamp, A., Maenpaa, J., Cruickshank, D., Ledermann, J., Wilkinson, P., Welch, R., Chan, S., Vasey, P., Sorbe, B., Hindley, A. & Jayson, G (2006). SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer. Br J Cancer, 94(1), 55-61. eScholarID:82783
• Cummings J, Ranson M, Lacasse E, Ganganagari JR, St-Jean M, Jayson G, Durkin J, Dive C. (2006). Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer, 42-48. eScholarID:89821
• Cummings, J., Ranson, M., Lacasse, E., Ganganagari, J., St-Jean, M., Jayson, G., Durkin, J. & Dive, C (2006). Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer, 95(1), 42-8. eScholarID:82778
• Duff, S., Jeziorska, M., Rosa, D., Kumar, S., Haboubi, N., Sherlock, D., O'Dwyer, S. & Jayson, G (2006). Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. Eur J Cancer, 42(1), 112-7. eScholarID:82785
• Jayson, G. & Harris, J (2006). How participants in cancer trials are chosen: ethics and conflicting interests. Nat Rev Cancer, 6(4), 330-6. eScholarID:82780
• Parker, G., Roberts, C., Macdonald, A., Buonaccorsi, G., Cheung, S., Buckley, D., Jackson, A., Watson, Y., Davies, K. & Jayson, G (2006). Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med, 56(5), 993-1000. eScholarID:82776
• Rosa D, Harris JM, Jayson GC. (2006). The best guess approach to phase I clinical trial design. 206-208. eScholarID:89813
• Rosa DD, Clamp A, Mullamitha S, Ton NC, Lau S, Byrd L, Clayton R, Slade RJ, Kitchener HC, Shanks JH, Wilson G, McVey R, Hasan J, Swindell R, Jayson GC. (2006). The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma. Eur J Surg Oncol, 588-591. eScholarID:89819
• Rosa, D., Clamp, A., Mullamitha, S., Ton, N., Lau, S., Byrd, L., Clayton, R., Slade, R., Kitchener, H., Shanks, J., Wilson, G., McVey, R., Hasan, J., Swindell, R. & Jayson, G (2006). The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma. Eur J Surg Oncol, 32(5), 588-91. eScholarID:82779
• Rosa, D., Harris, J. & Jayson, G (2006). The best guess approach to phase I trial design. J Clin Oncol, 24(1), 206-8. eScholarID:82784
• Whitworth MK, Sheen A, Rosa DD, Duff SE, Ryder D, Burumdayal A, Wiener K, Hawkins RE, Saunders M, Valle JW, Sherlock D, Jayson GC. (2006). Impact Of Laparotomy And Liver Resection On The Peritoneal Concentrations Of Fibroblast Growth Factor 2, Vascular Endothelial Growth Factor And Hepatocyte Growth Factor. J Cancer Res Clin Oncol, 41-44. eScholarID:89814
• Whitworth, M., Sheen, A., Rosa, D., Duff, S., Ryder, D., Burumdayal, A., Wiener, K., Hawkins, R., Saunders, M., Valle, J., Sherlock, D. & Jayson, G (2006). Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factor. J Cancer Res Clin Oncol, 132(1), 41-4. eScholarID:82786

2005

• Buonaccorsi GA, Roberts C, Cheung S, Watson Y, Davies K, Jackson A, Jayson GC, Parker GJ. (2005). Tracer kinetic model-driven registration for dynamic contrast enhanced MRI time series. Med Image Comput Comput Assist Interv Int Conf Med Image Comput Comput Assist Interv, 2005(8), 91-98. eScholarID:142388
• Clamp A, Jayson G-. (2005). Profiling heparan sulfate proteoglycans in ovarian carcinoma. ScientificWorldJournal, 5, eScholarID:1d30759
• Clamp A, Jayson G-. (2005). The clinical potential of antiangiogenic fragments of extracellular matrix proteins. Br J Cancer, 93( 9), eScholarID:1d30758
• Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, Coleman R, Jayson G, Le T, Ellard S, Trudeau1 M, Vasey P, Hamilton M, Cameron T, Barrett E, Walsh W, McIntosh L, Eisenhauer E. (2005). Randomised Trial of Two Intravenous Schedules of the Liposomal Topoisomerase I Inhibitor, OSI-211, in Women With Relapsed Epithelial Ovarian Cancer. A Trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 1859-1866. eScholarID:89749
• Duff S, Saunders M, McCredie V, Kumar S, O'Dwyer S, Jayson G-. (2005). Pre-operative plasma levels of vascular endothelial growth factor A, C and D in patients with colorectal cancer. Clin Oncol (R Coll Radiol), 17( 5), eScholarID:1d30086
• Duff SE, Saunders M, McCredie V, Kumar S, O'Dwyer ST, Jayson. (2005). Pre-operative plasma levels of VEGF-A, VEGF-C and VEGF-D in patients with colorectal cancer. Clin Oncol (R Coll Radiol), 367-371. eScholarID:89806
• Hasan J, Ton N, Mullamitha S, Clamp A, McNeilly A, Marshall E, Jayson G-. (2005). Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. Br J Cancer, 93( 6), eScholarID:1d31100
• Hasan J, Ton N, Mullamitha S, Clamp A, McNeilly A, Marshall E, Jayson GC. (2005). Phase II Trial Of Tamoxifen And Goserelin For The Treatment Of Recurrent Epithelial Ovarian Cancer. 647-651. eScholarID:89807
• Hasan, J, Shnyder, S, Clamp, A, McGown, A, Bicknell, R, Presta, M, Bibby, M, Double, J, Craig, S, Leeming, D, Stevenson, K, Gallagher, JT, Jayson, G-. (2005). Heparin octasaccharides inhibit angiogenesis in vivo. Clin Cancer Res, 11( 22), 8172-9. eScholarID:1d12942 | DOI:10.1158/1078-0432.CCR-05-0452
• Jayson G-, Armand J, Berdel W. (2005). [Inhibition of angiogenesis by proteins, peptides and "small molecules"]. Onkologie, 28 Suppl 4, eScholarID:1d31268
• Jayson GC, Mulatero C, Ranson M, Zweit J, Jackson A, Broughton L, Wagstaff J, Hakansson L, Groenewegen G, Lawrance J, Tang M, Wauk L, Levitt D, Marreaud S, Lehmann FF, Herold M, Zwierzina H. (2005). Phase I Investigation Of Recombinant Anti-Human Vascular Endothelial Growth Factor Antibody In Patients With Advanced Cancer. Eur J Cancer, 555-563. eScholarID:89750
• Jayson GC, Parker GJM, Mullamitha S, Valle JW, Saunders M, Broughton L, Lawrance J, Carrington B, Roberts C, Issa B, Buckley DL, Cheung S, Davies K, Watson Y, Zinkewich-Péotti K, Rolfe L, Jackson A. (2005). Blockade of PDGF receptor beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and increased tumor vascularised volume. J Clin Oncol, 973-981. eScholarID:89747
• Jayson, G, Jayson, G-, Parker, G, Mullamitha, S, Valle, JW, Saunders, M, Broughton, L, Lawrance, J, Carrington, B, Roberts, C, Issa, B, Buckley, D, Cheung, S, Davies, K, Watson, Y, Zinkewich-Péotti, K, Rolfe, L, Jackson, A. (2005). Blockade of Platelet-Derived Growth Factor Receptor-Beta by CDP860, a Humanized, PEGylated di-Fab', Leads to Fluid Accumulation and Is Associated With Increased Tumor Vascularized Volume. J Clin Oncol, 5, 973-81. eScholarID:1d28735
• Jayson, G-, Mulatero, C, Ranson, MR, Zweit, J, Jackson, A, Broughton, L, Wagstaff, J, Hakansson, L, Groenewegen, G, Lawrance, J, Tang, M, Wauk, L, Levitt, D, Marreaud, S, Lehmann, F, Herold, M, Zwierzina, H, NULL. (2005). Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. Eur J Cancer, 41( 4), 555-63. eScholarID:1d28906
• Lau S, Rosa D, Jayson G-. (2005). Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis. Curr Opin Mol Ther, 7( 5), eScholarID:1d30365
• Ranson MR, Jayson G-. (2005). Targeted antitumour therapy--future perspectives. Br J Cancer, 92 Suppl 1, S28-31. eScholarID:1d29452
• Rehman S, Jayson G-. (2005). Molecular imaging of antiangiogenic agents. Oncologist, 10( 2), eScholarID:1d30945
• Shnyder SD, Hasan J, Cooper PA, Pilarinou E, Jubb E, Jayson GC, Bibby MC. (2005). Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature. Anticancer Res, 1889-1894. eScholarID:89751
• Ward T, Danson S, McGown A, Ranson MR, Coe N, Jayson G-, Cummings J, Hargreaves R, Butler J. (2005). Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone. Clin Cancer Res, 11( 7), 2695-701. eScholarID:1d30983
• Ward TH, Danson S, Coe N, McGown AT, Ranson M, Disley L, Jayson GC, Butler J. (2005). Pre-Clinical evaluation of the Pharmacodynamic Properties of RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone). Clin Cancer Res, 2695-2701. eScholarID:89804
• Whitworth MK, Backen AC, Clamp AR, Wilson G, McVey R, Friedl A, Rapraeger AC, David G, McGown A, Slade RJ, Gallagher JT, Jayson GC. (2005). Regulation of Fibroblast Growth Factor-2 Activity by Human Ovarian Cancer Tumor Endothelium. Clin Cancer Res, 4282-4288. eScholarID:89803
• Whitworth, M, Backen, A, Clamp, A, Wilson, G, McVey, R, Friedl, A, Rapraeger, A, David, G, McGown, A, Slade, R, Gallagher, JT, Jayson, G-. (2005). Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium. Clin Cancer Res, 11( 12), 4282-8. eScholarID:1d11457 | DOI:10.1158/1078-0432.CCR-04-1386
• Winter-Roach B, Hooper L, Jayson G, Kitchener HC. (2005). Adjuvant (post-surgical) chemotherapy for early stage epithelial ovarian cancer (Protocol). The Cochrane collaboration, eScholarID:89805

2004

• 35 Clamp A, Adams M, Atkinson R, Boven E, Calvert AH, Cervantes A, Ganesan T, Lotz J, Vasey P, Cheverton P and Jayson GC. (2004). A Phase IIA study of the topoisomerase-1 inhibitor, exatecan mesylate (DX-8951f) administered at 2 different dose schedules in patients with platinum and taxane resistant/refractory ovarian cancer. Gyne. Oncol, 114-119. eScholarID:89745
• Clamp, A, Adams, M, Atkinson, R, Boven, E, Calvert, A, Cervantes, A, Ganesan, T, Lotz, J, Vasey, P, Cheverton, P, Jayson, G-. (2004). A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer. Gynecol Oncol, 95( 1), eScholarID:1d9248
• Davies EJ, Blackhall FH, Shanks JH, David G, McGown AT, Swindell R, Slade RJ, Martin-Hirsch P, Gallagher JT, Jayson GC. (2004). Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res, 5178-5186. eScholarID:89744
• Davies, E, Blackhall, FH, Shanks, J, David, G, McGown, A, Swindell, R, Slade, R, Martin-Hirsch, P, Gallagher, JT, Jayson, G-. (2004). Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res, 10( 15), 5178-86. eScholarID:1d29112
• Hasan J, Shnyder S, Bibby M, Double J, Bicknel R, Jayson G-. (2004). Quantitative angiogenesis assays in vivo--a review. Angiogenesis, 7( 1), eScholarID:1d29001
• He X, Brenchley P, Jayson GC, Hampson L, Davies J, Hampson I. (2004). Hypoxia Increases Heparanase Dependent Tumor Cell Invasion Which Can Be Inhibited by Anti-heparanase Antibodies. Cancer Research, 3928-3933. eScholarID:89743
• Hipkins J, Whitworth M, Tarrier N, Jayson G. (2004). Social support, anxiety and depression after chemotherapy for ovarian cancer: A prospective study. Br J Health Psychol, 569-581. eScholarID:89734
• Ton N, Jayson G-. (2004). Resistance to anti-VEGF agents. Curr Pharm Des, 10( 1), eScholarID:1d29113
• Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB. (2004). On behalf of the Scottish Gynaecological Cancer Trials Group. Phase III Randomized Trial of Docetaxel–Carboplatin Versus Paclitaxel–Carboplatin as First-line Chemotherapy for Ovarian Carcinoma. J Natl Cancer Inst, 1682-1691. eScholarID:89746
• Vasey, P, Jayson, G-, Gordon, A, Gabra, H, Coleman, R, Atkinson, R, Parkin, D, Paul, J, Hay, A, Kaye, S. (2004). Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst, 96( 22), 1682-91. eScholarID:1d9274 | DOI:10.1093/jnci/djh323
• Whitworth M, Whitfield A, Holm S, Shaffer J, Jayson G-. (2004). Doctor, does this mean I'm going to starve to death? J Clin Oncol, 22( 1), eScholarID:1d29239
• Whitworth M, Whitfield AM, Makin WP, Shaffer J, Holm S, Jayson GC. (2004). Does this mean I am going to starve to death doctor? J Clin Oncol, 199-201. eScholarID:89733
• Xiaotong HE, Brenchley PEC, Jayson G-, Hampson L, Davies J, Hampson IN. (2004). Hypoxia increases heparanase dependent tumour cell invasion which can be inhibited by anti-heparanase antibodies. Cancer Research, 3928-3933. eScholarID:1d26159

2003

• Blackhall F.H, Merry C, Lyon M, Jayson G-, Folkman J, Javaherian K, Gallagher JT. (2003). Binding of endostatin to endothelial heparan sulphate shows a differential requirement for specific sulphates. J Biol Chem, eScholarID:1d33687
• Blackhall FH, Merry CLR, Javaherian K, Jayson G, Folkman J, Gallagher JT. (2003). Binding of Endostatin to Endothelial Heparan Sulphate Shows a Differential Requirement for Specific Sulphates. Biochem, 131-139. eScholarID:89731
• Clamp A, Blackhall FH, Vasey P, Soukop M, Coleman R, Halbert G, Robson L, Jayson G-. (2003). A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma. Br J Cancer, 89( 7), eScholarID:1d9250
• Clamp AR, Blackhall FH, Vasey P, Soukop M, Coleman R, Halbert G, Robson L and Jayson GC. (2003). A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma. Br J Cancer, 1152-1154. eScholarID:89732
• Duff S, Li C, Jeziorska M, Kumar S, Saunders M, Sherlock D, O'Dwyer S, Jayson G-. (2003). Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer, 89( 3), eScholarID:1d28683
• Harris M, Delap LM, Sengupta PS, Shanks J, Wilson G, Wilkinson PM, Welch R, Slade RJ, Reynolds K, Jayson GC. (2003). Carcinosarcoma of the ovary. Br J. Cancer, 654-657. eScholarID:89701
• Hasan J and Jayson GC. (2003). Melphalan in patients with platinum resistant ovarian cancer. Br. J. Cancer, 1828-1830. eScholarID:89729
• Hasan J, Jayson G-. (2003). Oral melphalan as a treatment for platinum-resistant ovarian cancer. Br J Cancer, 88( 12), eScholarID:1d29240
• Jackson A, Jayson GC, Li KL, Zhu XP, Checkley DR, Tessier JJL, Waterton JC. (2003). Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. Br. J. Radiol, 153-162. eScholarID:89699
• Jayson G-. (2003). Dose intensity in ovarian cancer. MIMS advances in Ovarian Cancer, eScholarID:1d33814
• Jayson G-. (2003). HRT after a diagnosis of epithelial ovarian cancer. MIMS advances in Ovarian Cancer, eScholarID:1d33538
• Jayson G-. (2003). Ovarian cancer. British Oncology Pharmacists Association Newsletter, eScholarID:1d33884
• Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Trope C. (2003). ICON and AGO Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet, 2099-2106. eScholarID:89730
• Parmar, M, Ledermann, J, Colombo, N, du Bois, A, Delaloye, J, Kristensen, G, Wheeler, S, Swart, A, Qian, W, Torri, V, Floriani, I, Jayson, G-, Lamont, A, Tropé, C. (2003). Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet, 361( 9375), 2099-106. eScholarID:1d29683
• Smith E, Jayson G-. (2003). The current and future management of malignant ascites. Clin Oncol (R Coll Radiol), 15( 2), eScholarID:1d29114
• Smith E, Jayson G-. (2003). The management of malignant ascites. Clinical Oncology, 15, eScholarID:1d33685
• Jackson A-, Jayson G-, Li K-, Zhu X-, Checkley DR, Tessier JJL, Waterton JC. Reproductibility of quanitative dynamic contrast-enhanced MRI in newly-presenting glioma. Vol. 76. 2003. 153-162. eScholarID:19d263

2002

• 131 Lacombe D, Fumoleau P, Zwierzina H, Twelves C, Hakannson L, Jayson G, Lehmann F, Verweij J. (2002). The EORTC and drug development. Eur. J. Cancer, (38), 19-23. eScholarID:85828
• Clamp A, Jayson G-. (2002). The clinical development of the bryostatins. Anticancer Drugs, 13, eScholarID:1d2165
• Clamp A, Jayson G-. (2002). Weekly platinum chemotherapy for recurrent ovarian cancer. Br J Cancer, 86, eScholarID:1d2167
• Hasan J, Byers RJ, Jayson G-. (2002). Intra-tumoural microvessel density in human solid tumours. British Journal Of Cancer, 86, eScholarID:1d25112
• Jackson A-, Hamied Haroon, Zhu X-, Li K-, Thacker NA, Jayson G-. (2002). Breath Hold Perfusion and Permeability Mapping of Hepatic Malignancies Using Magnetic Resonance Imaging and a First-pass Leakage Profile Model. NMR in Biomedicine, 15, eScholarID:1d1918
• Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, Broughton L, Wagstaff J, Hakannson L, Groenewegen G, Bailey J, Smith N, Hastings D, Lawrance J, Ward T, McGown AT, Tang T, Levitt D, Marreaud S, Lehmann FF, Herold M, Zwierzina H. (2002). Molecular Imaging and Biological evaluation of HuMV833 anti-VEGF antibody: Implications for trial design of anti-angiogenic antibodies. J. Natl. Cancer Inst, 1484-1493. eScholarID:89698
• Jayson GC. (2002). Current Medical Literature in Gynaecological Oncology, eScholarID:85830
• Jayson GC. (2002). Current Medical Literature in Gynaecological Oncology, eScholarID:85832
• Jayson GC. (2002). Current Medical Literature in Gynaecological Oncology, eScholarID:85833
• Ranson MR, Mansoor A, Jayson G-. (2002). ZD1839 (Iressa) a selective epidermal growth factor receptor tyrosine kinase inhibitor. Anti Cancer Drugs, 2, eScholarID:1d33883

2001

• Blackhall FH Davies EJ, Merry C, Jayson G-. (2001). Heparan sulfate proteoglycans and cancer. Br J Cancer, 85, eScholarID:1d2169
• Blackhall FH Hancock BW Soukop M McGown AT Robbins A Halbert G, Cancer Research Campaign Phase I/II Committee, Ranson MR, Radford JA, Jayson G-. (2001). A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. Br J Cancer, 84, eScholarID:1d2170
• Hasan J, Jayson G-. (2001). VEGF antagonists. Expert Opin Biol Ther, 1, eScholarID:1d2168
• Holm S and Jayson GC. (2001). What do patients, their relatives and medical staff know about gene therapy? 13-19. eScholarID:89695

2000

• Sengupta PS, McGown AT, Bajaj V, Blackhall F, Swindell R, Bromley M, Shanks JH, Ward T, Buckley CH, Reynolds K, Slade RJ, Jayson GC. (2000). P53 And related proteins in epithelial ovarian cancer. Eur J Cancer, 2317-2328. eScholarID:89691
• Sengupta PS, Shanks JH, Buckley CH, Ryder WDJ, Davies J, Reynolds K, Slade RJ, Kitchener HC, Jayson GC. (2000). Requirement For Expert Histopathological Assessment Of Ovarian Tumours. BJC, 760-762. eScholarID:89686
• Wardley AM Swindell R Morgenstern GR Chang J Bloor R Fraser CJ Scarffe JH, Jayson G-. (2000). Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol, 110, eScholarID:1d2175
• White S, Anderson H, Ashcroft L, Jayson GC, Ranson M, Thatcher N. (2000). Randomised phase II study of cisplatin and etoposide versus infusional carboplatin in advanced non-small cell lung cancer and mesothelioma. Annals of Oncology, 11, 201-206. eScholarID:89687
• Wrigley E, Verspaget HW, Jayson GC, McGown AT. (2000). Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance. J Cancer Res Clin Oncol, 717-721. eScholarID:89690

1999

• Jayson GC, Vives C, Paraskeva C, Schofield K, Coutts J, Fleetwood A, Gallagher JT. (1999). The coordinated modulation of the fibroblast growth factor dual receptor mechanism during transformation from human colon adenoma to carcinoma. Int J Cancer, 298-304. eScholarID:89685
• Sengupta PS Slade RJ Eardley A, Jayson G-, Radford JA. (1999). An audit of primary surgical treatment for women with ovarian cancer referred to a cancer centre. Br J Cancer, 80, eScholarID:1d2178
• Sengupta PS, Jayson GC, Slade R, Eardley A, Radford JA. (1999). An audit of surgery performed for ovarian cancer in the North West of England. British J Cancer, 444-447. eScholarID:89684
• Vives C Paraskeva C Schofield K Coutts J Fleetwood A, Jayson G-, Gallagher JT. (1999). Coordinated modulation of the fibroblast growth factor dual receptor mechanism during transformation from human colon adenoma to carcinoma. Int J Cancer, 82, eScholarID:1d2179

1998

• Adams M A'Hern RP Calvert AH Carmichael J, Jayson G-, Kaye SB Ledermann JA Osborne RJ Perren TJ, Poole CJ Rustin GJ Slevin ML Smyth JF Thomas H Wilkinson PM, Radford JA, Clark PI Coleman RE Earl HM Gallagher CJ, Ganesan TS Gore ME Graham JD Harper PG. (1998). Chemotherapy for ovarian cancer--a consensus statement on standard practice. Br J Cancer, 78, eScholarID:1d2180
• Jayson G-, Middleton M Lee SM Ashcroft L, Thatcher N. (1998). A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer. Br J Cancer, 78, eScholarID:1d2182
• Jayson GC, Lyon M, Paraskeva C, Turnbull JE, Deakin JA, Gallagher JT. (1998). Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J. Biol. Chem, eScholarID:88480
• Jayson GC, Middleton M, Lee SM, Ashcroft L, Thatcher N. (1998). . A randomised phase II trial of Interleukin 2 and Interleukin 2/ interferon  in advanced renal cancer. British J. Cancer, eScholarID:88482
• Khan P, McGown AT, Dawson MJ, Jayson G, Prendiville JA, Pettit GR, Crowther D. (1998). High performance liquid chromatographic assay for the novel anti-cancer drug, bryostatin-1, incorporating a serum extraction technique. J. Chromatography B, eScholarID:88481
• McGown AT, Jayson G, Pettit GR, Haran MS, Ward TH Crowther D. (1998). Bryostatin 1 tamoxifen combinations show synergistic effects on the inhibition of P388 cells in vitro. Br. J. Cancer, eScholarID:88479
• Wardley AM, Jayson GC, Goldsmith DJA, Venning MC, Ackrill P. Scarffe JH. (1998). The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. Br J Cancer, eScholarID:88483

1997

• Jayson GC, Gallagher JT. (1997). Heparin oligosaccharides: Inhibitors of the biological activity of bFGF on Caco-2 cells. British Journal of Cancer, eScholarID:88477
• Ranson MR, Jayson G, Perkins S, Anderson H, Thatcher N. (1997). Single-agent paclitaxel in advanced non-small cell lung cancer: single-center phase II study using a 3-hour administration schedule. Semin. Oncol, eScholarID:88478

1996

• Ranson M, Jayson G, Thatcher N. (1996). The management of lung cancer in the elderly. Geriatric medicine, (26), 47-49. eScholarID:85826
• Wrigley E, Weaver A, Jayson G, Ranson M, Renninson J, Prendiville J, Dobson M, Collins CD, Swindell R, Buckley CH, Radford J, Crowther D. (1996). A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: A comparison of alternating combination chemotherapy given every four weeks for six cycles with the same dose of chemotherapy given at three week intervals. Annals of Oncology, eScholarID:88476

1995

• Ferguson JE, Hulse P, Lorigan P, Jayson G, Scarffe JH. (1995). Continuous infusion of 5-Fluorouracil with Alpha-2b interferon for advanced colorectal carcinoma. British Journal of Cancer, eScholarID:88474
• Jayson GC, CrowtherD, Prendiville J, McGown A, Scheid C, Stern P, Young R, Brenchley P, Chang J, Owens S, Pettit GR. (1995). A phase I trial of bryostatin-1 in patients with advanced malignancy using a 24 hour intravenous infusion. eScholarID:88475

1994

• Jayson GC, Evans GS, Pemberton PW, Lobley RW, Allen T. (1994). Basic Fibroblast Growth Factor increases the multiplication and migration of a serum free derivative of Caco-2 but does not affect differentiation. Cancer Research, eScholarID:88473
• Jayson GC, Howell A, Harris M, Morgenstern GR, Chang J, Ryder D. (1994). Carcinomatous meningitis in breast cancer: An aggressive disease variant. Cancer, eScholarID:88469
• Scheid C, Prendiville J, Jayson GC, Crowther D, Fox B, Pettit GR, Stern PL. (1994). Immunomodulation in patients receiving intravenous bryostatin 1 in a phase I clinical study: Comparison with effects of bryostatin 1 on lymphocyte function in vitro. Cancer Immunol. Immunother, 1994. eScholarID:88472

• Brookes, K., Cummings, J., Backen, A., Greystoke, A., Ward, T., Jayson, G. & Dive, C Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. Br J Cancer, 102(10), 1524-32. eScholarID:82806
• Goncalves, V., Jayson, G. & Tarrier, N A longitudinal investigation of psychological disorders in patients prior and subsequent to a diagnosis of ovarian cancer. J Clin Psychol Med Settings, 17(2), 167-73. eScholarID:82810
• Hasan J, Jayson G-. VEGF antagonists as anti-cancer agents. American Journal of Oncology, eScholarID:1d33686
• Mitchell, C., O'Connor, J., Jackson, A., Parker, G., Roberts, C., Watson, Y., Cheung, S., Davies, K., Buonaccorsi, G., Clamp, A., Hasan, J., Byrd, L., Backen, A., Dive, C. & Jayson, G Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy. Ann Oncol, eScholarID:82807
• Murukesh, N., Dive, C. & Jayson, G Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer, 102(1), 8-18. eScholarID:82738
• Zee, Y., Chan, S., Harris, J. & Jayson, G The ethical and scientific case for phase 2C clinical trials. Lancet Oncol, 11(5), 410-1. eScholarID:82805
• Zee, Y., O'Connor, J., Parker, G., Jackson, A., Clamp, A., Taylor, M., Clarke, N. & Jayson, G Imaging angiogenesis of genitourinary tumors. Nat Rev Urol, 7(2), 69-82. eScholarID:82808